MCP inhibits urokinase-type plasminogen activator (uPA) synthesis in breast and prostate cancer cells, and the uPA receptor (uPAR) regulates cell adhesion, migration, and invasion [14]. The gene discussed is PLAU; the disease is prostate carcinoma.